{"id":5095,"date":"2021-02-24T18:11:41","date_gmt":"2021-02-25T02:11:41","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=5095"},"modified":"2021-02-24T18:11:41","modified_gmt":"2021-02-25T02:11:41","slug":"janssen-ad26-cov2-s-vaccine-for-the-prevention-of-covid-19-vaccines-and-related-biological-products-advisory-committee-meeting","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/24\/janssen-ad26-cov2-s-vaccine-for-the-prevention-of-covid-19-vaccines-and-related-biological-products-advisory-committee-meeting\/","title":{"rendered":"Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting"},"content":{"rendered":"<p>The Johnson &amp; Johnson single-dose Ad26.COV2.S vaccine candidate was determined by the FDA to have met the safety and efficacy requirements for emergency use authorization. Vaccine efficacy against laboratory-confirmed moderate to severe\/critical COVID-19 across all geographic areas in which the trial was conducted was 66.9% when considering cases occurring at least 14 days after the single-dose vaccination and 66.1% considering cases occurring at least 28 days after vaccination. Efficacy against severe\/critical COVID-19 occurring at least 14 days and at least 28 days after vaccination was 76.7% and 85.4%, respectively. As of February 5, 2021, there were 7 COVID-19 related deaths in the placebo group and no COVID-19 related deaths in the vaccine group. A subset of participants (n=6,736) was followed for self-reported reactions to the vaccine within 7 days following vaccination, and the most common adverse reactions were mild to moderate injection site pain (48.6%), headache (38.9%), fatigue (38.2%), and myalgia (33.2%).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><i>FDA. (Feb 26, 2021). Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19. Vaccines and Related Biological Products Advisory Committee Meeting. <\/i><a href=\"https:\/\/www.fda.gov\/media\/146217\/download\">https:\/\/www.fda.gov\/media\/146217\/download<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Johnson &amp; Johnson single-dose Ad26.COV2.S vaccine candidate was determined by the FDA to have met the safety and efficacy requirements for emergency use authorization. Vaccine efficacy against laboratory-confirmed moderate to severe\/critical COVID-19 across all geographic areas in which the trial was conducted was 66.9% when considering cases occurring at least 14 days after the&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/24\/janssen-ad26-cov2-s-vaccine-for-the-prevention-of-covid-19-vaccines-and-related-biological-products-advisory-committee-meeting\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-5095","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=5095"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5095\/revisions"}],"predecessor-version":[{"id":5096,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/5095\/revisions\/5096"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=5095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=5095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=5095"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=5095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}